title: [Anti-atherosclerotic and anti-inflammatory effects of statin on cardiovascular disease and their mechanisms].
abstract: Inflammation plays a central role in the development of atherosclerosis and plaque rupture. Statin not only inhibits cholesterol synthesis but also elicits pleiotropic effects by blocking mevalonate pathyway and the isoprenylation of small GTPases which are involved in vascular responses. High sensitive C-reactive protein (hsCRP) is a prognostic biomarker for vascular inflammation. JUPITER trial focusing on hsCRP has shown that inflammation is a key player for cardiovascular disease independent of cholesterol levels. Japanese clinical trials of MEGA and MUSASHI-AMI also demonstrated that statin is beneficial for primary and secondary prevention of cardiovascular events via both cholesterol-lowering and pleiotropic effects. Our recent animal study of intravenous administration of pravastatin supports the rapid pleiotropic effects of statin beyond cholesterol-lowering.
authors.affiliation: Ohara Medical Center Hospital.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Ishibashi
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000209:etiology / Q000517:prevention & control; D008798:Mevalonic Acid / Q000378:metabolism; D020559:Monomeric GTP-Binding Proteins / Q000378:metabolism; D058226:Plaque, Atherosclerotic / Q000209:etiology; D017035:Pravastatin; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020559:Monomeric GTP-Binding Proteins; D017035:Pravastatin; D008798:Mevalonic Acid